Symbols / XAGE $0.28 -4.10% Longevity Health Holdings, Inc.
XAGE Chart
About
Longevity Health Holdings, Inc., a bio-aesthetics company, focuses on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company utilizes Carmell Secretome and Elevai Exosomes to support skin and hair health. Its Carmell Secretome consists of growth factors, proteins, and peptides extracted from allogeneic human platelets; and Elevai Exosomes constains growth factors, cytokines, peptides, and other small molecules involved in the body's natural healing process. The company also develops a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Corporation and changed its name to Longevity Health Holdings, Inc. in March 2025. Longevity Health Holdings, Inc. was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Consumer Defensive | Industry | Household & Personal Pro | Market Cap | 694.46K |
| Enterprise Value | 488.70K | Income | -6.91M | Sales | 1.91M |
| Book/sh | -2.23 | Cash/sh | 0.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 0.36 | P/B | -0.13 | P/C | — |
| EV/EBITDA | -0.07 | EV/Sales | 0.26 | Quick Ratio | 0.09 |
| Current Ratio | 0.25 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.83 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 26.06% | Earnings | — | ROA | -233.29% |
| ROE | — | ROIC | — | Gross Margin | 54.05% |
| Oper. Margin | -5.70% | Profit Margin | 0.00% | Shs Outstand | 2.47M |
| Shs Float | 2.36M | Short Float | 0.59% | Short Ratio | 0.27 |
| Short Interest | — | 52W High | 9.30 | 52W Low | 0.25 |
| Beta | — | Avg Volume | 1.90K | Volume | 5.00K |
| Target Price | — | Recom | None | Prev Close | $0.29 |
| Price | $0.28 | Change | -4.10% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- New Longevity Health chief takes equity stake to lead acquisition push - Stock Titan ue, 17 Mar 2026 07
- Longevity Health (OTC: XAGE) updates prospectus; 44,382 shares registered, $0.39 last sale - Stock Titan ue, 31 Mar 2026 20
- XAGE Shares Surge: Should You Dive In? - StocksToTrade ue, 15 Jul 2025 07
- Longevity Health Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com ue, 31 Mar 2026 20
- Longevity Health Appoints New CEO Amid Strategic Shift - tipranks.com ue, 17 Mar 2026 07
- Why did XAGE Stock Surge in Today’s Premarket Trading? - Tokenist ue, 15 Jul 2025 07
- Longevity Health Holdings and THPlasma to Merge - citybiz Mon, 14 Jul 2025 07
- Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs - GlobeNewswire Wed, 21 May 2025 07
- Longevity Health Holdings to remain listed on Nasdaq ahead of planned merger - The Business Journals hu, 22 May 2025 07
- Longevity Health (OTCQB: XAGE) raises $200K and installs Ram Ajjarapu as CEO - Stock Titan ue, 17 Mar 2026 07
- Longevity Health Holdings, Inc. (XAGE) stock price, news, quote and history - Yahoo Finance UK ue, 18 Mar 2025 09
- Longevity Health Soars On Merger Deal With True Health - RTTNews ue, 15 Jul 2025 07
- Longevity Health to combine with 20/20 BioLabs in all-stock deal (XAGE:NASDAQ) - Seeking Alpha Mon, 14 Apr 2025 07
- Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction - GlobeNewswire Mon, 14 Jul 2025 07
- XAGE Stock Price, News & Analysis - Stock Titan hu, 24 Apr 2025 17
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.91
+3701.44%
|
0.05
|
0.00
|
0.00
|
| Operating Revenue |
|
2.15
+2269.58%
|
0.09
|
0.00
|
0.00
|
| Cost Of Revenue |
|
0.82
+12768.51%
|
0.01
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
0.68
+10623.17%
|
0.01
|
0.00
|
—
|
| Gross Profit |
|
1.09
+2390.30%
|
0.04
|
0.00
|
—
|
| Operating Expense |
|
8.20
+62.67%
|
5.04
-3.35%
|
5.22
-5.27%
|
5.51
|
| Research And Development |
|
0.79
-25.17%
|
1.05
-57.78%
|
2.50
+13.71%
|
2.20
|
| Selling General And Administration |
|
7.33
+87.85%
|
3.90
+48.87%
|
2.62
-18.47%
|
3.22
|
| Selling And Marketing Expense |
|
1.42
+651.65%
|
0.19
|
0.00
|
—
|
| General And Administrative Expense |
|
5.91
+59.12%
|
3.72
+41.65%
|
2.62
-18.47%
|
3.22
|
| Other Gand A |
|
5.91
+59.12%
|
3.72
+41.65%
|
2.62
-18.47%
|
3.22
|
| Total Expenses |
|
9.02
+78.66%
|
5.05
-3.23%
|
5.22
-5.27%
|
5.51
|
| Operating Income |
|
-7.11
-42.19%
|
-5.00
+4.19%
|
-5.22
+5.27%
|
-5.51
|
| Total Operating Income As Reported |
|
-7.11
-42.19%
|
-5.00
+15.90%
|
-5.94
-7.91%
|
-5.51
|
| EBITDA |
|
-6.64
+36.81%
|
-10.50
+30.87%
|
-15.19
-200.25%
|
-5.06
|
| Normalized EBITDA |
|
-6.72
-41.37%
|
-4.76
+5.32%
|
-5.02
+4.39%
|
-5.25
|
| Reconciled Depreciation |
|
0.22
+9.02%
|
0.20
+58.08%
|
0.12
-48.55%
|
0.24
|
| EBIT |
|
-6.85
+35.97%
|
-10.70
+30.15%
|
-15.32
-188.86%
|
-5.30
|
| Total Unusual Items |
|
0.09
+101.54%
|
-5.75
+43.50%
|
-10.17
-5324.92%
|
0.19
|
| Total Unusual Items Excluding Goodwill |
|
0.09
+101.54%
|
-5.75
+43.50%
|
-10.17
-5324.92%
|
0.19
|
| Special Income Charges |
|
0.09
+298.80%
|
-0.04
+93.86%
|
-0.73
+31.78%
|
-1.06
|
| Other Special Charges |
|
—
|
0.04
|
—
|
1.06
|
| Restructuring And Mergern Acquisition |
|
-0.15
|
0.00
-100.00%
|
0.73
|
0.00
|
| Write Off |
|
0.06
|
0.00
|
—
|
—
|
| Net Income |
|
-6.91
+33.40%
|
-10.37
+32.87%
|
-15.45
-70.64%
|
-9.05
|
| Pretax Income |
|
-6.87
+36.09%
|
-10.75
+33.68%
|
-16.21
-79.04%
|
-9.05
|
| Net Non Operating Interest Income Expense |
|
-0.02
+62.84%
|
-0.05
+94.49%
|
-0.89
+76.28%
|
-3.75
|
| Interest Expense Non Operating |
|
0.02
-62.84%
|
0.05
-94.49%
|
0.89
-76.28%
|
3.75
|
| Net Interest Income |
|
-0.02
+62.84%
|
-0.05
+94.49%
|
-0.89
+76.28%
|
-3.75
|
| Interest Expense |
|
0.02
-62.84%
|
0.05
-94.49%
|
0.89
-76.28%
|
3.75
|
| Other Income Expense |
|
0.26
+104.50%
|
-5.70
+43.55%
|
-10.10
-5013.78%
|
0.21
|
| Other Non Operating Income Expenses |
|
0.17
+275.34%
|
0.04
-34.86%
|
0.07
+529.66%
|
0.01
|
| Gain On Sale Of Security |
|
—
|
-5.70
+39.62%
|
-9.44
-849.72%
|
1.26
|
| Tax Provision |
|
0.04
+137.28%
|
-0.10
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+2220.19%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.02
+135.79%
|
-0.05
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-6.91
+33.40%
|
-10.37
+32.87%
|
-15.45
-70.64%
|
-9.05
|
| Net Income From Continuing Operation Net Minority Interest |
|
-6.91
+35.16%
|
-10.65
+34.28%
|
-16.21
-79.04%
|
-9.05
|
| Net Income From Continuing And Discontinued Operation |
|
-6.91
+33.40%
|
-10.37
+32.87%
|
-15.45
-70.64%
|
-9.05
|
| Net Income Continuous Operations |
|
-6.91
+35.16%
|
-10.65
+34.28%
|
-16.21
-79.04%
|
-9.05
|
| Net Income Discontinuous Operations |
|
0.00
-100.00%
|
0.28
-62.88%
|
0.76
|
0.00
|
| Normalized Income |
|
-6.98
-40.70%
|
-4.96
+17.89%
|
-6.04
+34.70%
|
-9.25
|
| Net Income Common Stockholders |
|
-6.91
+33.40%
|
-10.37
+35.69%
|
-16.12
-67.79%
|
-9.61
|
| Diluted EPS |
|
—
|
-14.56
+66.76%
|
-43.80
-192.31%
|
-14.98
|
| Basic EPS |
|
—
|
-14.56
+66.76%
|
-43.80
-192.31%
|
-14.98
|
| Basic Average Shares |
|
—
|
0.71
+93.83%
|
0.37
-42.71%
|
0.64
|
| Diluted Average Shares |
|
—
|
0.71
+93.83%
|
0.37
-42.71%
|
0.64
|
| Diluted NI Availto Com Stockholders |
|
-6.91
+33.40%
|
-10.37
+35.69%
|
-16.12
-67.79%
|
-9.61
|
| Amortization |
|
0.08
-5.76%
|
0.08
-14.03%
|
0.10
|
—
|
| Amortization Of Intangibles Income Statement |
|
0.08
-5.76%
|
0.08
-14.03%
|
0.10
|
—
|
| Depreciation Amortization Depletion Income Statement |
|
0.08
-5.76%
|
0.08
-14.03%
|
0.10
+2.99%
|
0.09
|
| Depreciation And Amortization In Income Statement |
|
0.08
-5.76%
|
0.08
-14.03%
|
0.10
+2.99%
|
0.09
|
| Preferred Stock Dividends |
|
—
|
—
|
0.68
+21.48%
|
0.56
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
2.04
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
63.95
|
| Current Assets |
|
62.90
|
| Cash Cash Equivalents And Short Term Investments |
|
2.91
|
| Cash And Cash Equivalents |
|
2.91
|
| Cash Financial |
|
2.91
|
| Receivables |
|
0.20
|
| Accounts Receivable |
|
0.00
|
| Taxes Receivable |
|
0.20
|
| Inventory |
|
0.00
|
| Prepaid Assets |
|
0.76
|
| Current Deferred Assets |
|
0.00
|
| Assets Held For Sale Current |
|
53.32
|
| Hedging Assets Current |
|
5.70
|
| Other Current Assets |
|
—
|
| Total Non Current Assets |
|
1.05
|
| Net PPE |
|
1.02
|
| Gross PPE |
|
1.65
|
| Accumulated Depreciation |
|
-0.62
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.00
|
| Other Properties |
|
1.53
|
| Leases |
|
0.12
|
| Goodwill And Other Intangible Assets |
|
0.02
|
| Other Intangible Assets |
|
0.02
|
| Total Liabilities Net Minority Interest |
|
39.20
|
| Current Liabilities |
|
38.50
|
| Payables And Accrued Expenses |
|
5.90
|
| Payables |
|
4.42
|
| Accounts Payable |
|
4.42
|
| Other Payable |
|
—
|
| Current Accrued Expenses |
|
1.48
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.29
|
| Total Tax Payable |
|
—
|
| Current Debt And Capital Lease Obligation |
|
1.44
|
| Current Debt |
|
1.29
|
| Other Current Borrowings |
|
1.29
|
| Current Capital Lease Obligation |
|
0.15
|
| Other Current Liabilities |
|
29.87
|
| Total Non Current Liabilities Net Minority Interest |
|
0.70
|
| Long Term Debt And Capital Lease Obligation |
|
0.70
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.70
|
| Tradeand Other Payables Non Current |
|
—
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
| Stockholders Equity |
|
24.75
|
| Common Stock Equity |
|
24.75
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.77
|
| Ordinary Shares Number |
|
0.77
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
83.25
|
| Retained Earnings |
|
-58.50
|
| Total Equity Gross Minority Interest |
|
24.75
|
| Total Capitalization |
|
24.75
|
| Working Capital |
|
24.40
|
| Invested Capital |
|
26.04
|
| Total Debt |
|
2.14
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
0.85
|
| Net Tangible Assets |
|
24.72
|
| Tangible Book Value |
|
24.72
|
| Derivative Product Liabilities |
|
—
|
| Interest Payable |
|
1.18
|
| Preferred Stock Equity |
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.33
+14.49%
|
-3.89
+53.36%
|
-8.35
-143.48%
|
-3.43
|
| Cash Flow From Continuing Operating Activities |
|
-3.33
+14.49%
|
-3.89
+53.36%
|
-8.35
-143.48%
|
-3.43
|
| Net Income From Continuing Operations |
|
-6.91
+33.40%
|
-10.37
+32.87%
|
-15.45
-70.64%
|
-9.05
|
| Depreciation Amortization Depletion |
|
0.22
+9.02%
|
0.20
+58.08%
|
0.12
-48.55%
|
0.24
|
| Depreciation |
|
0.14
+19.87%
|
0.11
+311.11%
|
0.03
-88.37%
|
0.24
|
| Amortization Cash Flow |
|
0.08
-5.76%
|
0.08
-14.03%
|
0.10
+2050.42%
|
0.00
|
| Depreciation And Amortization |
|
0.22
+9.02%
|
0.20
+58.08%
|
0.12
-48.55%
|
0.24
|
| Amortization Of Intangibles |
|
0.08
-5.76%
|
0.08
-14.03%
|
0.10
+2050.42%
|
0.00
|
| Other Non Cash Items |
|
-0.15
+89.43%
|
-1.41
-595.57%
|
0.29
-89.02%
|
2.60
|
| Stock Based Compensation |
|
0.69
-16.23%
|
0.83
+23.87%
|
0.67
+4.92%
|
0.64
|
| Asset Impairment Charge |
|
0.06
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
—
|
5.70
-39.62%
|
9.44
+4951.69%
|
-0.19
|
| Gain Loss On Investment Securities |
|
—
|
5.70
-39.62%
|
9.44
+849.72%
|
-1.26
|
| Change In Working Capital |
|
2.76
+136.60%
|
1.17
+134.05%
|
-3.42
-246.34%
|
2.34
|
| Change In Receivables |
|
0.35
+441.30%
|
-0.10
+50.44%
|
-0.20
|
0.00
|
| Changes In Account Receivables |
|
0.04
+1177.91%
|
-0.00
|
0.00
|
—
|
| Change In Inventory |
|
0.37
+441.16%
|
-0.11
|
0.00
|
—
|
| Change In Prepaid Assets |
|
0.54
-43.96%
|
0.96
+245.40%
|
-0.66
-1098.36%
|
-0.06
|
| Change In Payables And Accrued Expense |
|
1.64
+200.12%
|
-1.64
-207.01%
|
-0.53
-120.99%
|
2.55
|
| Change In Accrued Expense |
|
1.52
+218.27%
|
-1.28
-378.13%
|
0.46
-69.00%
|
1.49
|
| Change In Payable |
|
0.13
+135.32%
|
-0.36
+63.92%
|
-1.00
-193.90%
|
1.06
|
| Change In Account Payable |
|
0.13
+135.32%
|
-0.36
+20.17%
|
-0.45
-142.44%
|
1.06
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.12
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
4.66
-75.41%
|
18.97
+67416.87%
|
-0.03
|
| Change In Other Current Liabilities |
|
-0.14
+94.61%
|
-2.61
+87.58%
|
-20.99
-16713.38%
|
-0.12
|
| Investing Cash Flow |
|
-0.16
+78.07%
|
-0.75
-2357.49%
|
-0.03
-325.32%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.16
+78.07%
|
-0.75
-2357.49%
|
-0.03
-325.32%
|
-0.01
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
+100.00%
|
-0.03
-325.32%
|
-0.01
|
| Purchase Of PPE |
|
-0.01
|
0.00
+100.00%
|
-0.03
-325.32%
|
-0.01
|
| Capital Expenditure |
|
-0.01
|
—
|
-0.03
-325.32%
|
-0.01
|
| Net Business Purchase And Sale |
|
-0.15
+79.97%
|
-0.75
|
0.00
|
—
|
| Purchase Of Business |
|
-0.15
+79.97%
|
-0.75
|
0.00
|
—
|
| Financing Cash Flow |
|
4.04
+114.29%
|
1.89
-83.10%
|
11.16
+214.30%
|
3.55
|
| Cash Flow From Continuing Financing Activities |
|
4.04
+114.29%
|
1.89
-83.10%
|
11.16
+214.30%
|
3.55
|
| Net Issuance Payments Of Debt |
|
-0.44
+38.29%
|
-0.71
+46.77%
|
-1.34
-148.86%
|
2.75
|
| Issuance Of Debt |
|
—
|
0.50
-73.35%
|
1.86
-32.27%
|
2.75
|
| Repayment Of Debt |
|
-0.44
+38.29%
|
-0.71
+77.69%
|
-3.20
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
2.75
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
2.75
|
| Short Term Debt Issuance |
|
—
|
0.50
-73.35%
|
1.86
-32.27%
|
2.75
|
| Short Term Debt Payments |
|
-0.44
+38.29%
|
-0.71
+77.69%
|
-3.20
|
0.00
|
| Net Short Term Debt Issuance |
|
-0.44
+38.29%
|
-0.71
+46.77%
|
-1.34
-148.86%
|
2.75
|
| Net Common Stock Issuance |
|
3.48
+29.64%
|
2.69
|
0.00
+100.00%
|
-0.00
|
| Common Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-0.00
|
| Proceeds From Stock Option Exercised |
|
1.00
|
0.00
-100.00%
|
0.04
-71.91%
|
0.15
|
| Net Other Financing Charges |
|
—
|
-0.09
-100.69%
|
12.46
+3196.14%
|
-0.40
|
| Changes In Cash |
|
0.55
+119.95%
|
-2.76
-198.96%
|
2.78
+2304.68%
|
0.12
|
| Beginning Cash Position |
|
0.16
-94.60%
|
2.91
+2172.71%
|
0.13
+936.64%
|
0.01
|
| End Cash Position |
|
0.71
+349.75%
|
0.16
-94.60%
|
2.91
+2172.71%
|
0.13
|
| Free Cash Flow |
|
-3.34
+14.12%
|
-3.89
+53.53%
|
-8.38
-143.86%
|
-3.44
|
| Interest Paid Supplemental Data |
|
0.02
-38.19%
|
0.03
-89.61%
|
0.28
+206.21%
|
0.09
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
-100.00%
|
0.75
|
0.00
|
| Change In Income Tax Payable |
|
—
|
0.00
+100.00%
|
-0.55
|
0.00
|
| Change In Interest Payable |
|
—
|
0.00
+100.00%
|
-0.11
-110.35%
|
1.06
|
| Change In Tax Payable |
|
—
|
0.00
+100.00%
|
-0.55
|
0.00
|
| Common Stock Issuance |
|
3.48
+29.64%
|
2.69
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
3.48
+29.64%
|
2.69
|
0.00
-100.00%
|
1.06
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
1.06
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
1.06
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-17 View
- 8-K2025-12-12 View
- 10-Q2025-11-14 View
- 8-K2025-11-07 View
- 8-K2025-09-12 View
- 10-Q2025-08-14 View
- 8-K2025-07-14 View
- 8-K2025-06-25 View
- 8-K2025-05-28 View
- 8-K2025-05-21 View
- 8-K2025-05-16 View
- 10-Q2025-05-15 View
- 8-K2025-05-12 View
- 8-K2025-04-14 View
- 8-K2025-04-03 View
- 10-K2025-03-31 View
- 8-K2025-03-26 View
- 8-K2025-03-10 View
- 8-K2025-03-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|